Read by QxMD icon Read

International Journal of Antimicrobial Agents

Marion Nicol, Mohamed Amine Ben Mlouka, Thierry Berthe, Patrick Di Martino, Thierry Jouenne, Jean-Michel Brunel, Emmanuelle Dé
Squalamine is a natural polycationic aminosterol extracted from Squalus acanthias. It displays a remarkable efficacy against Gram- and Gram+ bacteria which are resistant to antimicrobials. Its membranolytic activity and its low cytotoxicity make squalamine one of the most promising agents to fight against nosocomial pathogens such as Acinetobacter baumannii. In the context of chronic diseases and therapeutic failures associated to this pathogen, the presence of dormant cells, i.e. persisters and viable but not culturable cells (VBNCs), highly tolerant to antimicrobial compounds is problematic...
November 10, 2018: International Journal of Antimicrobial Agents
Laurent Poirel, Nicolas Kieffer, Patrice Nordmann
No abstract text is available yet for this article.
November 8, 2018: International Journal of Antimicrobial Agents
Sharad Vats, Asheesh Shanker
BACKGROUND: Drug resistance has been associated with point mutations in the coding regions, which lead to an altered protein sequence and structure. Such changes have been seen as isolated events which occur at various positions in a sequence. However, we hypothesize that it is not a single mutation at a specific position instead a group of positions which coevolve in a correlated fashion to increase the fitness of target protein against a drug. METHODS: Scientific literature was searched to identify drug resistance genes relevant to the current first-line multidrug regimen (Isoniazid, Rifampicin, Ethambutol, and Pyrazinamide), used to treat tuberculosis caused by Mycobacterium tuberculosis...
November 8, 2018: International Journal of Antimicrobial Agents
Matteo Bassetti, Nadia Castaldo, Annamaria Cattelan, Cristina Mussini, Elda Righi, Carlo Tascini, Francesco Menichetti, Claudio Maria Mastroianni, Mario Tumbarello, Paolo Grossi, Stefania Artioli, Novella Carrannante, Ludovica Cipriani, Davide Coletto, Alessandro Russo, Margherita Digaetano, Raffaella Losito, Maddalena Peghin, Alessandro Capone, Stefano Nicolè, Antonio Vena
To describe the largest clinical experience using ceftolozane-tazobactam (C/T) for treatment of different type of Pseudomonas aeruginosa infections. A retrospective study was performed at 22 hospitals in Italy from June 2016 to March 2018. All adult patients treated with at least 4 days of C/T were enrolled. A successful clinical outcome was defined as complete resolution of clinical signs and symptoms related to P. aeruginosa infection and lack of microbiological evidence of infection. C/T treatment was documented in 101 patients with diverse infections, including nosocomial pneumonia (31...
November 8, 2018: International Journal of Antimicrobial Agents
Ronald G Hall, Eunice Yoo, Andrew Faust, Terri Smith, Edward Goodman, Eric M Mortensen, Jaffar Raza, Farbod Dehmami, Carlos A Alvarez
Piperacillin/tazobactam has been associated with nephrotoxicity in patients receiving vancomycin. Its impact on nephrotoxicity in patients with gram-negative bacteremia (GNB) is unclear. This study aims to evaluate piperacillin/tazobactam's impact on nephrotoxicity in patients with GNB. Our retrospective cohort included patients ≥18 years of age who received ≥48 hours of therapy for bacteremia due to Escherichia coli, Pseudomonas aeruginosa, Enterobacter sp., Klebsiella sp., Acinetobacter sp., or Stenotrophomonas maltophila from 1/1/2008-8/31/2011...
November 8, 2018: International Journal of Antimicrobial Agents
Noriyuki Nagano, Shota Koide, Wataru Hayashi, Yui Taniguchi, Hayato Tanaka, Yoshihiko Maeyama, Masahiro Suzuki, Kouji Kimura, Yoshichika Arakawa, Yukiko Nagano
Over a 35-month period, group B Streptococcus isolates with reduced penicillin susceptibility (PRGBS) were detected from elderly patients at a regional hospital, accompanying population-level transition of PRGBS serotypes. Seventy-seven non-duplicate PRGBS recovered from 73 patients were analyzed to infer their genetic relatedness. Serotype III PRGBS predominated (16 serotype III/1 serotype Ib) in the first nine months (period I), then 3 serotype Ib isolates appeared transiently for the next three months (period II), which was replaced predominantly by serotype Ia (20 serotype Ia/1 serotype III/1 nontypeable) for nine months (period III)...
November 7, 2018: International Journal of Antimicrobial Agents
Sabrina Klein, Monja-Dorina Menz, Philipp Zanger, Klaus Heeg, Dennis Nurjadi
Methicillin-resistant Staphylococcus aureus (MRSA) remains a major challenge for patient care. Community-associated MRSA (CA)-MRSA often have fitness and virulence advantage compared to their nosocomial counterpart. Increased mobility, travel activities and migration accelerate the intercontinental spread of virulent CA-MRSA. Out-patient clinics are the most important route of entry for CA-MRSA into hospitals. However, systematic data on CA-MRSA in Germany is limited. We characterized community onset MRSA SSTI isolates in the Rhine-Neckar Region from 2012-2016 to gain insight into the molecular epidemiology and monitor potential introduction of virulent and dominant MRSA strains into our hospital...
November 6, 2018: International Journal of Antimicrobial Agents
R J van de Peppel, M T van der Beek, L G Visser, M G J de Boer, J Wallinga
OBJECTIVES: Triazole resistance in Aspergillus spp. is emerging and complicates prophylaxis and treatment of Invasive Aspergillosis (IA) worldwide. New Polymerase Chain Reaction (PCR) tests on broncho-alveolar lavage (BAL) fluid allow for detection of triazole-resistance on a genetic level, which opened up new possibilities for targeted therapy. In the absence of clinical trials, a modelling study delivers estimates of the added value of resistance detection with PCR and which empiric therapy would be optimal when local resistance rates are known...
November 2, 2018: International Journal of Antimicrobial Agents
Antonios Papadopoulos, Alba Ribera, Andreas Mavrogenis, Dolors Rodriguez-Pardo, Eric Bonnet, Mauro José Salles, María Dolores Del Toro, Sophie Nguyen, Antonio Blanco García, Gábor Skaliczki, Alejandro Soriano, Natividad Benito, Sabine Petersdorf, Maria Bruna Pasticci, Pierre Tattevin, Zeliha Kocak Tufan, Monica Chan, Nuala O' Connell, Nikos Pantazis, Aikaterini Kyprianou, Carlοs Pigrau, Panayiotis Megaloikonomos, Eric Senneville, Javier Ariza Cardenal, Panayiotis Papagelopoulos, Efthymia Giannitsioti
OBJECTIVE: We analyze factors influencing the treatment outcome of patients with Gram negative (GNB) multi-drug (MDR) and extensively-drug (XDR) resistant prosthetic joint infection (PJI). METHODS: Data were collected from 2000-2015 by 18 centers, endorsed by ESGIAI (European Study Group for Implant Associated Infections). Treatment success was analyzed by the type of surgery for PJI, the type of resistance (MDR/XDR) and antimicrobials (colistin vs non-colistin) through logistic regression and survival analysis...
November 2, 2018: International Journal of Antimicrobial Agents
Agnès B Jousset, Sandrine Bernabeu, Remy A Bonnin, Elodie Creton, Garance Cotellon, Aimie Sauvadet, Thierry Naas, Laurent Dortet
Plasmid-mediated colistin resistance is increasingly described worldwide in Enterobacteriaceae from animal and from human isolates. Diffusion of these resistance traits among carbapenem-resistant enterobacterial isolates is particularly worrisome, since colistin has become the last resort antibiotic for treating human infections with these organisms. Therefore, being able to monitor the presence of these transferable colistin resistance genes (mcr-1 to mcr-5-variants) is crucial. Here, we have developed a multiplex polymerase chain reaction (PCR) protocol for detection of all currently known transferable colistin resistance genes in Enterobacteriaceae...
November 2, 2018: International Journal of Antimicrobial Agents
Stefan Ebmeyer, Erik Kristiansson, D G Joakim Larsson
To investigate the origin of the PER extended-spectrum beta-lactamase, publicly available sequence databases were searched for PER-like genes. Three genomes from Pararheinheimera, a genus associated with water and soil environments, were found to carry PER-like genes, but lacked the ISCR1/ISPa12/ISPa13 insertion sequences (IS) commonly associated with PER in clinical isolates. Sequence analysis revealed 78-96% nucleotide identity and conserved synteny between the clinical mobile genetic elements (MGEs) encoding PER-1 and the PER locus in the Pararheinheimera genomes...
November 2, 2018: International Journal of Antimicrobial Agents
Garyfallia Poulakou, Georgios Renieris, Labros Sabrakos, Olympia Zarkotou, Katherine Themeli-Digalaki, Efstathia Perivolioti, Eleni Kraniotaki, Evangelos J Giamarellos-Bourboulis, Nikolaos Zavras
The emergence of Acinetobacter baumannii with resistance to colistin (ABRC) led to investigation if daptomycin can be used as adjunctive to colistin for these isolates. One ABRC carbapenemase-producing bloodstream isolate was studied; minimum inhibitory concentrations of imipenem was >512 μg/ml, of daptomycin >512μg/ml and of colistin 8 μg/ml. First, a "humanized" model of pharmacokinetics of daptomycin and colistin was developed in 18 C57Bl6 male mice. Then, 112 mice were infected by the intraperitoneal injection of the ABRC isolate and randomly assigned into four groups of once daily treatment for seven days; A: controls treated with saline; B treated with 20mg/kg of colistin; C: treated with 50mg/kg of daptomycin; and D; treated with both agents...
November 1, 2018: International Journal of Antimicrobial Agents
Allyson Andrade Mendonça, Marcos Antonio de Morais, Manuel Zúñiga Cabrera
No abstract text is available yet for this article.
October 31, 2018: International Journal of Antimicrobial Agents
D Fage, G Deprez, F Wolff, M Hites, F Jacobs, F Van Bambeke, F Cotton
Colistin, used as a last resort drug, has a narrow therapeutic range that justifies therapeutic drug monitoring. Few data are available in the literature concerning the in vivo unbound fraction of colistin. The objectives of this study were to develop a method to isolate unbound colistin in clinical samples by ultrafiltration and to quantify it. The association between unbound colistin and biological parameters (total protein, albumin, alpha-1-acid glycoprotein, and creatinine) was investigated. The measured ranges were 0...
October 31, 2018: International Journal of Antimicrobial Agents
T Kostyanev, T Vilken, C Lammens, L Timbermont, A Van't Veen, H Goossens
Antimicrobial resistance (AMR) represents a global public health threat which jeopardizes the progress that modern medicine has made over the last century. To confront AMR, the Innovative Medicines Initiative (IMI) has supported the development of a large network of hospitals and laboratories in Europe as part of the New Drugs for Bad Bugs (ND4BB) programme and the COMBACTE projects. COMBACTE LAB-Net conducted a pilot survey on distribution and usage of carbapenem resistance detection methods among laboratories in the COMBACTE network at the occasion of two clinical trials as part of the COMBACTE-CARE project...
October 31, 2018: International Journal of Antimicrobial Agents
M Tobias Heinrichs, George L Drusano, David L Brown, Michael S Maynard, Sherwin K B Sy, Kenneth H Rand, Charles A Peloquin, Arnold Louie, Hartmut Derendorf
INTRODUCTION: There is an urgent need for new anti-TB drugs and an optimization of current TB treatment. Moxifloxacin and linezolid are valuable options for the treatment of drug-resistant TB, however, it is crucial to find a dose, at which these drugs not only show high efficacy but also can suppress the development of further drug resistance. METHODS: Activity of moxifloxacin and linezolid against M. tuberculosis was studied in the hollow fiber infection model system in log-phase growth under neutral pH and slow growth in an acidic environment...
October 29, 2018: International Journal of Antimicrobial Agents
Martha Yumiko Cruz-Muñiz, Luis Esau López-Jacome, Melissa Hernández-Durán, Rafael Franco-Cendejas, Paula Licona-Limón, Jose Luis Ramos-Balderas, Mariano Martinéz-Vázquez, Javier A Belmont-Díaz, Thomas K Wood, Rodolfo García-Contreras
No abstract text is available yet for this article.
October 29, 2018: International Journal of Antimicrobial Agents
Nadège Néant, Caroline Solas
The advent of direct acting antiviral agents (DAAs) has transformed the Hepatitis C virus (HCV) therapeutic landscape in terms of efficacy and safety with a cure rate of more than 90%. However, an important potential for drug-drug interactions (DDIs) is expected with these combinations, especially in patients with other comorbidities (HIV co-infection, cardiovascular diseases, ). Each DAA can be a substrate, an inhibitor and/or an inducer of metabolic enzymes and drug efflux transporters. DAAs can act as both victims and perpetrators of DDIs which can sometimes increase the risk and/or intensity of side effects or limit the efficacy of the treatment...
October 27, 2018: International Journal of Antimicrobial Agents
Despoina Koulenti, Andrew Song, Aaron Ellingboe, Mohd Hafiz Abdul-Aziz, Patrick Harris, Emile Gavey, Jeffrey Lipman
The spread of multidrug resistant bacteria is an ever-growing concern especially among Gram-negative ones due to their intrinsic resistance as well as their ability to acquire and spread new resistance mechanisms rapidly. The challenge to treat infections by these organisms leaves medical practitioners helpless to their treatment and increases patient mortality as well as cost of care globally. This vulnerability, along with strategies to tackle antimicrobial resistance development, prompts the development of new antibiotic agents as well as exploration of alternative treatment options...
October 27, 2018: International Journal of Antimicrobial Agents
Krystyna M Kazmierczak, Masakatsu Tsuji, Mark G Wise, Meredith Hackel, Yoshinori Yamano, Roger Echols, Daniel F Sahm
Cefiderocol is a siderophore cephalosporin in development for treatment of infections caused by Gram-negative bacilli including carbapenem-resistant and multidrug-resistant isolates. The β-lactamase carriage and in vitro activity of cefiderocol were determined against 1,272 meropenem-nonsusceptible isolates of Enterobacteriaceae, Pseudomonas aeruginosa and Acinetobacter baumannii collected as part of the SIDERO-WT-2014 surveillance study. MIC values for cefiderocol were ≤4 µg/mL against 97.7% of tested isolates, including 100% of IMP-positive (range, 1-2 µg/mL), OXA-58-positive (MIC90 , 1 µg/mL), KPC-positive (MIC90 , 2 µg/mL), VIM-positive (MIC90 , 2 µg/mL), and OXA-48-like-positive (MIC90 , 4 µg/mL) isolates; 99...
October 25, 2018: International Journal of Antimicrobial Agents
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"